Evidence map›Paper›PMID 11309678›Full record

ArticleAmerican journal of human genetics2001

Identification and expression analysis of spastin gene mutations in hereditary spastic paraplegia.

I K Svenson, A E Ashley-Koch, P C Gaskell, T J Riney, W J Cumming, H M Kingston, E L Hogan, R M Boustany, J M Vance, M A Nance and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 154 citations in OpenAlex.

  1. Late-Onset Hereditary Spastic Paraplegia with a NovelAnnals of laboratory medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Unraveling Isoform Complexity: The Roles of M1- and M87-Spastin in Spastic Paraplegia 4 (SPG4).Movement disorders : official journal of the Movement Disorder Society · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. A novel truncating variant ofFrontiers in neurology · 2022
    Article
  11. The Role of Spastin in Axon Biology.Frontiers in cell and developmental biology · 2022
    Review
  12. Review
  13. Therapeutic Strategies for MutantBrain sciences · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

I K SvensonDuke University Medical Center, Durham, NC 27710, USA.
A E Ashley-Koch
P C Gaskell
T J Riney
W J Cumming
H M Kingston
E L Hogan
R M Boustany
J M Vance
M A Nance
M A Pericak-Vance
D A Marchuk
Duke Medical Center · USMedical University of South Carolina · USPark Nicollet Clinic · USQueen Alexandra Hospital · GBSt. Mary's Hospital · GB

Funding

USE OF DNA PROBE FOR CHOLINERGIC AND NON-CHOLINERGIC MG ANTIGENP01NS026630 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI PERICAK-VANCE, MARGARET A. · 1989 to 2009
$12.6M
NINDS NIH HHS 2P01-NS26630-11A1NINDS NIH HHS P01 NS026630
6 · The paper itself

Abstract

Pure hereditary spastic paraplegia (SPG) type 4 is the most common form of autosomal dominant hereditary SPG, a neurodegenerative disease characterized primarily by hyperreflexia and progressive spasticity of the lower limbs. It is caused by mutations in the gene encoding spastin, a member of the AAA family of ATPases. We have screened the spastin gene for mutations in 15 families consistent with linkage to the spastin gene locus, SPG4, and have identified 11 mutations, 10 of which are novel. Five of the mutations identified are in noninvariant splice-junction sequences. Reverse transcription-PCR analysis of mRNA from patients shows that each of these five mutations results in aberrant splicing. One mutation was found to be "leaky," or partially penetrant; that is, the mutant allele produced both mutant (skipped exon) and wild-type (full-length) transcripts. This phenomenon was reproduced in in vitro splicing experiments, with a minigene splicing-vector construct only in the context of the endogenous splice junctions flanking the splice junctions of the skipped exon. In the absence of endogenous splice junctions, only mutant transcript was detected. The existence of at least one leaky mutation suggests that relatively small differences in the level of wild-type spastin expression can have significant functional consequences. This may account, at least in part, for the wide ranges in age at onset, symptom severity, and rate of symptom progression that have been reported to occur both among and within families with SPG linked to SPG4. In addition, these results suggest caution in the interpretation of data solely obtained with minigene constructs to study the effects of sequence variation on splicing. The lack of full genomic sequence context in these constructs can mask important functional consequences of the mutation.

Indexed as

Adenosine TriphosphatasesAdolescentAdultAgedAge of OnsetAnimalsBase SequenceCell LineChildChild, PreschoolDNA Mutational AnalysisExonsGenes, DominantHumansInfantIntronsAdenosine TriphosphatasesRNA, MessengerRNA Splice SitesSpastinSPAST protein, human

Identifiers

PMID11309678
PMCPMC1226088
OpenAlexW2165392243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.